Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ETV6-NTRK3 fusion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ETV6-NTRK3 fusion	Head and Neck Cancer	ETV6-NTRK3 fusion	Head and Neck Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ETV6-NTRK3 fusion	Solid Tumor	ETV6-NTRK3 fusion	Solid Tumor	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3
ETV6-NTRK3 fusion	Salivary Gland Cancer	ETV6-NTRK3 fusion	Salivary Gland Cancer	entrectinib Resistant: C3 – Early Trials entrectinib Resistant : C3	entrectinib Resistant: C3 – Early Trials entrectinib Resistant : C3
ETV6-NTRK3 fusion	Acute Myelogenous Leukemia	ETV6-NTRK3 fusion	Acute Myelogenous Leukemia	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3
ETV6-NTRK3 fusion	Salivary Gland Cancer	ETV6-NTRK3 fusion	Salivary Gland Cancer	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	Resistant: C4 – Case Studies Resistant : C4	Resistant: C4 – Case Studies Resistant : C4
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4
ETV6-NTRK3 fusion	Breast Cancer	ETV6-NTRK3 fusion	Breast Cancer	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
ETV6-NTRK3 fusion	Neuroendocrine Tumor	ETV6-NTRK3 fusion	Neuroendocrine Tumor	entrectinib Sensitive: C4 – Case Studies entrectinib Sensitive : C4	entrectinib Sensitive: C4 – Case Studies entrectinib Sensitive : C4
ETV6-NTRK3 fusion	Glioma	ETV6-NTRK3 fusion	Glioma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
ETV6-NTRK3 fusion	Soft Tissue Sarcoma	ETV6-NTRK3 fusion	Soft Tissue Sarcoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
ETV6-NTRK3 fusion	Triple Negative Breast Cancer	ETV6-NTRK3 fusion	Triple Negative Breast Cancer	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
ETV6-NTRK3 fusion	Neuroblastoma	ETV6-NTRK3 fusion	Neuroblastoma	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D
ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	larotrectinib Sensitive: D – Preclinical larotrectinib Sensitive : D	larotrectinib Sensitive: D – Preclinical larotrectinib Sensitive : D
ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	OPN-7486 Sensitive: D – Preclinical OPN-7486 Sensitive : D	OPN-7486 Sensitive: D – Preclinical OPN-7486 Sensitive : D
ETV6-NTRK3 fusion	Squamous Cell Carcinoma of Head and Neck	ETV6-NTRK3 fusion	Squamous Cell Carcinoma of Head and Neck	LY2801653 Sensitive: D – Preclinical LY2801653 Sensitive : D	LY2801653 Sensitive: D – Preclinical LY2801653 Sensitive : D